2026-04-17T19:01:48Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/129562025-10-24T02:03:09Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Park, Yeon Hee
author
Sohn, Joohyuk
author
Cortes, Javier
author
MUÑOZ COUSELO, EVA
author
Kim, Sung-Bae
author
Dent, Rebecca
2025-04-14T09:40:38Z2025-04-14T09:40:38Z2025-03-11
Immunohistochemistry; Triple-negative breast cancer; Tumor microenvironmentImmunohistoquímica; Càncer de mama triple negatiu; Microambient tumoralInmunohistoquímica; Cáncer de mama triple negativo; Microambiente tumoralBackground
The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the tumor microenvironment that might be predictive of response.
Methods
Cell fractions from 20 paired samples collected at baseline and after one cycle of neoadjuvant pembrolizumab prior to chemotherapy initiation were analyzed by spatial localization (tumor compartment, stromal compartment, or sum of tumor and stromal compartments [total tumor]) using three six-plex immunohistochemistry panels with T-cell, myeloid cell, and natural killer cell components. Area under the receiver operating characteristic curve (AUROC) was used to assess associations between immune subsets and gene expression signatures (T-cell–inflamed gene expression profile [TcellinfGEP] and 10 non-TcellinfGEP signatures using RNA sequencing) and pathologic complete response (pCR).
Results
At baseline, six immune subsets quantitated within the tumor compartment showed AUROC with 95% CIs not crossing 0.5, including CD11c+ cells (macrophage and dendritic cell [DC]: AUROC, 0.85; 95% confidence interval [CI] 0.63–1.00), CD11c+/MHCII+/CD163−/CD68− cells (DC: 0.76; 95% CI, 0.53–0.99), CD11c+/MHCII−/CD163−/CD68− cells (nonactivated/immature DC: 0.80; 95% CI 0.54–1.00), and CD11c+/CD163+ cells (M2 macrophage: 0.77; 95% CI 0.55–0.99). Other associations with pCR included baseline CD11c+/MHCII−/CD163−/CD68− (nonactivated/immature DC) within the total tumor (AUROC, 0.76; 95% CI 0.51–1.00) and the baseline CD11c/CD3 ratio within the tumor compartment (0.75; 95% CI 0.52–0.98). Changes in immune subsets following one cycle of pembrolizumab were not strongly associated with pCR. Although T-cell associations were relatively weak, specific CD8 subsets trended toward association. The AUROC for discriminating pCR based on TcellinfGEP was 0.55 (95% CI 0.25–0.85); when detrended by TcellinfGEP, AUROC varied for the non-TcellinfGEP signatures. TcellinfGEP expression trended higher in responders than in nonresponders when evaluating pCR.
Conclusions
Myeloid cell populations within the tumor compartment at baseline and TcellinfGEP show a promising trend toward an association with pCR in a small subgroup of patients with early-stage TNBC treated with neoadjuvant pembrolizumab plus chemotherapy.
Trial registration
ClinicalTrials.gov, NCT02622074; registration date, December 2, 2015.Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Mama - Càncer - Tractament
Quimioteràpia combinada
Anticossos monoclonals - Ús terapèutic
Mama - Càncer - Aspectes genètics
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
Other subheadings::Other subheadings::/therapeutic use
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado::tratamiento neoadyuvante
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
Otros calificadores::Otros calificadores::/uso terapéutico
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion